A. a). d). c). f). b).e). g). Figure S1. NAT2 expression in lymphocytes and monocytes from a healthy volunteer. PBMC from a healthy volunteer were simple.

Slides:

Advertisements

Similar presentations

Online supplementary material. Profound and persistent decrease of circulating dendritic cells is associated with ICU-acquired infection in patients with.

Advertisements

Flow Cytometry. Allows For Detection Of Surface Markers Of Cells Allows For Detection Of Intracellular Factors Allows Detection Of Secreted Factors By.

Isotype control Supplementary Figure S1. Strategy for gating CD11b+CD14-CD33+CD40+ myeloid cells. Singlets were gated from live cells shown in forward.

Supplemental Figure 1 A. EpCAM Gating Strategy Top Row: Histogram showing unstained BT474 cells with low fluorescent intensity of the EpCAM specific PE.

Introduction To Flow Cytometry By Noha Kamel. Flow cytometry is a method of measuring multiple physical and chemical characteristics of particles by optical.

IFNγIL-2TNFaIL-17A CD40 L MOPP DMSO CD4+ Supplemental figure 5A SEB isotype control isotype control isotype control CD69+ A.

Electrical Muscle Stimulation Induces an Increase of VEGFR2 on Circulating Hematopoietic Stem Cells in Patients With Diabetes Asa Hidmark, PhD, Ioannis.

Side Scatter Forward Scatter Lineage CD1c CD141 CD303 lineage negative

Volume 94, Issue 2, Pages (March 2014)

Volume 125, Issue 2, Pages (August 2003)

PANEL 1 All events Lymphocytes (FSC-A v SSC-A)

Clinical “cytokine storm” as revealed by monocyte intracellular flow cytometry: correlation of tumor necrosis factor α with severe gut graft-versus-host.

Representative flow cytometry dot plots from a healthy individual

Plot 4: A01 P0 CHO Count Events / μL % of This Plot % of All Mean FSC-A Mean SSC-A CV FSC-A CV SSC-A Median FSC-A Median SSC-A All 8,

Expression of IL-9 receptor α chain on human germinal center B cells modulates IgE secretion Lama M. Fawaz, PhD, Ehssan Sharif-Askari, PhD, Oumnia Hajoui,

Increased apoptosis of peripheral blood T cells following allogeneic hematopoietic cell transplantation by Ming-Tseh Lin, Li-Hui Tseng, Haydar Frangoul,

Alterations in blood leukocytes of G551D-bearing cystic fibrosis patients undergoing treatment with ivacaftor Preston E. Bratcher, Steven M. Rowe, Ginger.

Reduced Frequency of Regulatory T Cells in Peripheral Blood Stem Cell Compared to Bone Marrow Transplantations Céline Blache, Joe-Marc Chauvin, Aude.

Rabbit Anti T-Lymphocyte Globulin Induces Apoptosis in Peripheral Blood Mononuclear Cell Compartments and Leukemia Cells, While Hematopoetic Stem Cells.

A B C D CD4+ CD8+ Control Isotype Ab Anti-TNFa Ab Control Isotype Ab

Further Analysis of Interleukin-2 Receptor Subunit Expression on the Different Human Peripheral Blood Mononuclear Cell Subsets by Denis David, Lynda Bani,

Recipient-Derived Cells after Cord Blood Transplantation: Dynamics Elucidated by Multicolor FACS, Reflecting Graft Failure and Relapse Nobukazu Watanabe,

Primary human MNCs and MDMs are targets of ZIKV infection.

Immunologic defects in 22q11.2 deletion syndrome

CD300a is expressed on human B cells, modulates BCR-mediated signaling, and its expression is down-regulated in HIV infection by Rodolfo Silva, Susan Moir,

BÜHLMANN CAST® Assays Technical Presentation

Residual Cancer Lymphocytes in Patients With Chronic Lymphocytic Leukemia After Therapy Show Increased Expression of Surface Antigen CD52 Detected Using.

Clinical “cytokine storm” as revealed by monocyte intracellular flow cytometry: correlation of tumor necrosis factor α with severe gut graft-versus-host.

Alternative Activation of Human Plasmacytoid DCs In Vitro and in Melanoma Lesions: Involvement of LAG-3 Chiara Camisaschi, Annamaria De Filippo, Valeria.

CD134-Allodepletion Allows Selective Elimination of Alloreactive Human T Cells without Loss of Virus-Specific and Leukemia-Specific Effectors Xupeng.

Figure S2 Gating strategy of AT2 cells based on EpCAM and MHCII

Figure 5 Treatment with fingolimod raises the activation threshold of monocytes in MS Peripheral blood mononuclear cells from 8 healthy donors, 7 patients.

Identification, quantification and isolation of mesenchymal progenitor cells from osteoarthritic synovium by fluorescence automated cell sorting S Fickert,

Interaction of HSV-1 Infected Peripheral Blood Mononuclear Cells with Cultured Dermal Microvascular Endothelial Cells: a Potential Model for the Pathogenesis.

Use of EAS to define TCR-Vb3- and TCR-Cb1-expressing T cells

CD34+ cells from paroxysmal nocturnal hemoglobinuria (PNH) patients are deficient in surface expression of cellular prion protein (PrP c) Antonio M Risitano,

Increased Soluble CD226 in Sera of Patients with Cutaneous T-Cell Lymphoma Mediates Cytotoxic Activity against Tumor Cells via CD155 Naomi Takahashi,

Variable levels of cell surface and intracellular marker expression by HuT78 and HuT102 cells. Variable levels of cell surface and intracellular marker.

Human Treg cells express PlexinB1.

Volume 83, Issue 6, Pages (June 2013)

Flow cytometric analysis of putative progenitor cells.

Kathleen R. Bartemes, BA, Gail M. Kephart, BS, Stephanie J

Supplemental Digital Content 2 – Figure 1

Flow cytometry analysis of TNF-β- and IL-10-producing CD33+ cells.

Volume 135, Issue 1, Pages (July 2008)

Volume 125, Issue 2, Pages (August 2003)

Refer to word document for this table

Blockade of CD11a by Efalizumab in Psoriasis Patients Induces a Unique State of T-Cell Hyporesponsiveness Emma Guttman-Yassky, Yulia Vugmeyster, Michelle.

d a c b CD8 CD3 CD4 CD62L HLA-DR CD57 10% 85% 11% 76% 19% 60% 36% 66%

Supplemental Digital Content 3 – Figure 2

CD4+ CD56+ Blastic Tumor Cells Express CD101 Molecules

Expression of IL-9 receptor α chain on human germinal center B cells modulates IgE secretion Lama M. Fawaz, PhD, Ehssan Sharif-Askari, PhD, Oumnia Hajoui,

CD127low/- and FoxP3+ Expression Levels Characterize Different Regulatory T-Cell Populations in Human Peripheral Blood Sandra Klein, Cosima C. Kretz,

(A) HLA-E expression on the surface of CD14+ cells in patients with AS, HLA-B*2705, HLA-B*2709-positive and HLA-B27-negative HCs. Results are expressed.

Residual Cancer Lymphocytes in Patients With Chronic Lymphocytic Leukemia After Therapy Show Increased Expression of Surface Antigen CD52 Detected Using.

Figure 1 BG-12 treatment reduced total circulating B cells and had variable effects on memory B cells BG-12 treatment reduced total circulating B cells.

Sustained increases in numbers of pulmonary dendritic cells after respiratory syncytial virus infection Marc Beyer, MD, Holger Bartz, MD, Katharina Hörner,

CD27 expression on bovine γδ and CD4 T cells ex vivo and in response to mitogen. CD27 expression on bovine γδ and CD4 T cells ex vivo and in response to.

Figure 2 Fingolimod impairs induction of activation markers on human monocytes Peripheral blood mononuclear cells from healthy donors were briefly exposed.

The risk allele of rs affects TCR-mediated intracellular calcium flux in CD4+ T cells from subjects with T1D or RA. Previously frozen PBMCs from.

Plasmacytoid Dendritic Cells: A New Cutaneous Dendritic Cell Subset with Distinct Role in Inflammatory Skin Diseases Andreas Wollenberg, Sandra Günther,

Volume 84, Issue 1, Pages (July 2013)

Intracellular TNF-α and IL-4 expression in gated CD33+ monocytes by three-color flow cytometry. Intracellular TNF-α and IL-4 expression in gated CD33+

Melanoma patient monocytes have altered expression of inflammatory and surface markers. Melanoma patient monocytes have altered expression of inflammatory.

CD4+ and CD8+ TILs express surface CD137.

Flow cytometry analysis of intracellular cytokine expression in control PBMC (left set of panels) and following either PMA-ionomycin activation (middle.

Monocytes from melanoma patients are unresponsive to TLR3 agonists.

The Majority of Epidermal T Cells in Psoriasis Vulgaris Lesions can Produce Type 1 Cytokines, Interferon-γ, Interleukin-2, and Tumor Necrosis Factor-α,

Flow cytometric gating strategy used to identify CD69 surface expression on CD4 (left paired columns) and CD8 (right paired columns) T lymphocytes. Flow.

Surface CD4 and CD14 and intracellular TNF-α expression in PBMCs

Presentation transcript:

A. a). d). c). f). b).e). g). Figure S1. NAT2 expression in lymphocytes and monocytes from a healthy volunteer. PBMC from a healthy volunteer were simple immunostaining for surface markers (CD3, CD19 or CD56) or for intracellular NAT2. A) Unstained cells. a) Dot plots of FSC and SSC. b) Dot plots of the isotype control-FITC in the lymphocyte gate (P1). c) Histogram of isotype control-FITC in the lymphocyte gate. d) Histogram of isotype control-PE in the lymphocyte gate. e) Dot plots of isotype control-FITC in the monocyte gate (P5). f) Histogram of isotype control-FITC in the monocytes gate. g) Histogram of isotype control-PE in the monocyte gate.

B. a). d). c). f). b).e). g). Figure S1. NAT2 expression in lymphocytes and monocytes from a healthy volunteer. PBMC from a healthy volunteer were simple immunostaining for surface markers (CD3, CD19 or CD56) or for intracellular NAT2. B) Isotype control-FITC. a) Dot plots of FSC and SSC. b) Dot plots of the isotype control-FITC in the lymphocyte gate (P1). c) Histogram of isotype control- FITC in the lymphocyte gate. d) Histogram of isotype control-PE in the lymphocyte gate. e) Dot plots of isotype control-FITC in the monocyte gate (P5). f) Histogram of isotype control-FITC in the monocytes gate. g) Histogram of isotype control-PE in the monocyte gate.

C. a). d). c). f). b).e). g). Figure S1. NAT2 expression in lymphocytes and monocytes from a healthy volunteer. PBMC from a healthy volunteer were simple immunostaining for surface markers (CD3, CD19 or CD56) or for intracellular NAT2. C) Isotype control-PE. a) Dot plots of FSC and SSC. b) Dot plots of the isotype control-FITC in the lymphocyte gate (P1). c) Histogram of isotype control-FITC in the lymphocyte gate. d) Histogram of isotype control-PE in the lymphocyte gate. e) Dot plots of isotype control-FITC in the monocyte gate (P5). f) Histogram of isotype control-FITC in the monocytes gate. g) Histogram of isotype control-PE in the monocyte gate.

D. a). d). c). f). b).e). g). Figure S1. NAT2 expression in lymphocytes and monocytes from a healthy volunteer. PBMC from a healthy volunteer were simple immunostaining for surface marker (anti-CD3-PE). D) CD3+ lymphocytes. a) Dot plots of FSC and SSC. b) Dot plots of anti-CD3-PE in the lymphocyte gate (P1). c) Histogram of anti-CD3-PE in the lymphocyte gate. d) Histogram of anti-CD3-PE in the FITC-channel. e) Dot plots of anti-CD3-PE in the monocyte gate (P5). f) Histogram of anti-CD3-PE in the monocytes gate. g) Histogram of anti-CD3-PE in the monocyte gate and FITC-channel.

E. a). d). c). f). b).e). g). Figure S1. NAT2 expression in lymphocytes and monocytes from a healthy volunteer. PBMC from a healthy volunteer were simple immunostaining for surface marker (anti-CD19-PE). E) CD19+ lymphocytes. a) Dot plots of FSC and SSC. b) Dot plots of anti-CD19-PE in the lymphocyte gate (P1). c) Histogram of anti-CD19-PE in the lymphocyte gate. d) Histogram of anti- CD19-PE in the FITC-channel. e) Dot plots of anti-CD19-PE in the monocyte gate (P5). f) Histogram of anti-CD19-PE in the monocytes gate. g) Histogram of anti-CD19-PE in the monocyte gate and FITC-channel.

F. a). d). c). f). b). e). g). Figure S1. NAT2 expression in lymphocytes and monocytes from a healthy volunteer. PBMC from a healthy volunteer were simple immunostaining for surface marker (anti-CD56-PE). F) CD56+ lymphocytes. a) Dot plots of FSC and SSC. b) Dot plots of anti-CD56-PE in the lymphocyte gate (P1). c) Histogram of anti-CD56-PE in the lymphocyte gate. d) Histogram of anti- CD56-PE in the FITC-channel. e) Dot plots of anti-CD56-PE in the monocyte gate (P5). f) Histogram of anti-CD56-PE in the monocytes gate. g) Histogram of anti-CD56-PE in the monocyte gate and FITC-channel.

G. a). d). c). f). b).e). g). Figure S1. NAT2 expression in lymphocytes and monocytes from a healthy volunteer. PBMC from a healthy volunteer were simple immunostaining for intracellular NAT2. G) NAT2+ cells. a) Dot plots of FSC and SSC. b) Dot plots of anti-NAT2-FITC in the lymphocyte gate (P1). c) Histogram of anti-NAT2-FITC in the lymphocyte gate. d) Histogram of anti-NAT2-FITC in the PE channel. e) Dot plots of anti-NAT2-FITC in the monocyte gate (P5). f) Histogram of anti-NAT2-FITC in the monocytes gate. g) Histogram of anti-NAT2-FITC in the monocyte gate and PE-channel.

H. a). d). c).f). b).e). g). Figure S1. NAT2 expression in lymphocytes and monocytes from a tuberculosis patient. PBMC from a tuberculosis patient were simple immunostaining for surface markers (CD3, CD19 or CD56) or for intracellular NAT2. H) Unstained cells. a) Dot plots of FSC and SSC. b) Dot plots of the isotype control-FITC in the lymphocyte gate (P1). c) Histogram of isotype control- FITC in the lymphocyte gate. d) Histogram of isotype control-PE in the lymphocyte gate. e) Dot plots of isotype control-FITC in the monocyte gate (P5). f) Histogram of isotype control-FITC in the monocytes gate. g) Histogram of isotype control-PE in the monocyte gate.

I. a). d). c). f). b).e). g). Figure S1. NAT2 expression in lymphocytes and monocytes from a tuberculosis patient. PBMC from a tuberculosis patient were simple immunostaining for surface markers (CD3, CD19 or CD56) or for intracellular NAT2. I) Isotype control-FITC. a) Dot plots of FSC and SSC. b) Dot plots of the isotype control-FITC in the lymphocyte gate (P1). c) Histogram of isotype control-FITC in the lymphocyte gate. d) Histogram of isotype control-PE in the lymphocyte gate. e) Dot plots of isotype control-FITC in the monocyte gate (P5). f) Histogram of isotype control-FITC in the monocytes gate. g) Histogram of isotype control-PE in the monocyte gate.

J. a). d). c). f). b).e). g). Figure S1. NAT2 expression in lymphocytes and monocytes from a tuberculosis patient. PBMC from a tuberculosis patient were simple immunostaining for surface markers (CD3, CD19 or CD56) or for intracellular NAT2. J) Isotype control-PE. a) Dot plots of FSC and SSC. b) Dot plots of the isotype control-FITC in the lymphocyte gate (P1). c) Histogram of isotype control- FITC in the lymphocyte gate. d) Histogram of isotype control-PE in the lymphocyte gate. e) Dot plots of isotype control-FITC in the monocyte gate (P5). f) Histogram of isotype control-FITC in the monocytes gate. g) Histogram of isotype control-PE in the monocyte gate.

K. a). d). c). f). b).e). g). Figure S1. NAT2 expression in lymphocytes and monocytes from a tuberculosis patient. PBMC from a tuberculosis patient were simple immunostaining for surface marker (anti-CD3-PE). K) CD3+ lymphocytes. a) Dot plots of FSC and SSC. b) Dot plots of anti-CD3-PE in the lymphocyte gate (P1). c) Histogram of anti-CD3-PE in the lymphocyte gate. d) Histogram of anti- CD3-PE in the FITC-channel. e) Dot plots of anti-CD3-PE in the monocyte gate (P5). f) Histogram of anti-CD3-PE in the monocytes gate. g) Histogram of anti-CD3-PE in the monocyte gate and FITC-channel.

L. a). d). c). f). b).e). g). Figure S1. NAT2 expression in lymphocytes and monocytes from a tuberculosis patient. PBMC from a tuberculosis patient were simple immunostaining for surface marker (anti-CD19-PE). L) CD19+ lymphocytes. a) Dot plots of FSC and SSC. b) Dot plots of anti-CD19-PE in the lymphocyte gate (P1). c) Histogram of anti-CD19-PE in the lymphocyte gate. d) Histogram of anti-CD19-PE in the FITC-channel. e) Dot plots of anti-CD19-PE in the monocyte gate (P5). f) Histogram of anti-CD19-PE in the monocytes gate. g) Histogram of anti-CD19-PE in the monocyte gate and FITC-channel.

M. a). d). c). f). b).e). g). Figure S1. NAT2 expression in lymphocytes and monocytes from a tuberculosis patient. PBMC from a tuberculosis patient were simple immunostaining for surface marker (anti-CD56-PE). M) CD56+ lymphocytes. a) Dot plots of FSC and SSC. b) Dot plots of anti-CD56-PE in the lymphocyte gate (P1). c) Histogram of anti-CD56-PE in the lymphocyte gate. d) Histogram of anti-CD56-PE in the FITC-channel. e) Dot plots of anti-CD56-PE in the monocyte gate (P5). f) Histogram of anti-CD56-PE in the monocytes gate. g) Histogram of anti-CD56-PE in the monocyte gate and FITC-channel.

N. a). d). c). f). b).e). g). Figure S1. NAT2 expression in lymphocytes and monocytes from a tuberculosis patient. PBMC from a tuberculosis patient were simple immunostaining for intracellular NAT2. N) NAT2+ cells. a) Dot plots of FSC and SSC. b) Dot plots of anti-NAT2- FITC in the lymphocyte gate (P1). c) Histogram of anti-NAT2-FITC in the lymphocyte gate. d) Histogram of anti-NAT2-FITC in the PE channel. e) Dot plots of anti-NAT2-FITC in the monocyte gate (P5). f) Histogram of anti-NAT2-FITC in the monocytes gate. g) Histogram of anti-NAT2-FITC in the monocyte gate and PE-channel.

A. a). d). c). f). b).e). g). Figure S2. NAT2 expression in lymphocytes and monocytes from a healthy volunteer. PBMC from a healthy volunteer were double immunostaining for surface markers (CD3, CD19 or CD56) and for intracellular NAT2. A) CD3+NAT2+ cells. a) Dot plots of FSC and SSC. b) Dot plots of anti-CD3-PE and anti-NAT2-FITC in the lymphocyte gate (P1). c) Histogram of anti-NAT2- FITC in the lymphocyte gate. d) Histogram of anti-CD3-PE in the lymphocyte gate. e) Dot plots of anti-CD3-PE and anti-NAT2- FITC in the monocyte gate (P5). f) Histogram of anti-NAT2-FITC in the monocytes gate. g) Histogram of anti-CD3-PE in the monocyte gate.

B. a). d). c). f). b).e). g). Figure S2. NAT2 expression in lymphocytes and monocytes from a healthy volunteer. PBMC from a healthy volunteer were double immunostaining for surface markers (CD3, CD19 or CD56) and for intracellular NAT2. B) CD19+NAT2+ cells. a) Dot plots of FSC and SSC. b) Dot plots of anti-CD19-PE and anti-NAT2-FITC in the lymphocyte gate (P1). c) Histogram of anti- NAT2-FITC in the lymphocyte gate. d) Histogram of anti-CD19-PE in the lymphocyte gate. e) Dot plots of anti-CD19-PE and anti-NAT2-FITC in the monocyte gate (P5). f) Histogram of anti-NAT2-FITC in the monocytes gate. g) Histogram of anti-CD19- PE in the monocyte gate.

C. a). d). c). f). b).e). g). Figure S2. NAT2 expression in lymphocytes and monocytes from a healthy volunteer. PBMC from a healthy volunteer were double immunostaining for surface markers (CD3, CD19 or CD56) and for intracellular NAT2. C) CD56+NAT2+ cells. a) Dot plots of FSC and SSC. b) Dot plots of anti-CD56-PE and anti-NAT2-FITC in the lymphocyte gate (P1). c) Histogram of anti- NAT2-FITC in the lymphocyte gate. d) Histogram of anti-CD56-PE in the lymphocyte gate. e) Dot plots of anti-CD56-PE and anti-NAT2-FITC in the monocyte gate (P5). f) Histogram of anti-NAT2-FITC in the monocytes gate. g) Histogram of anti-CD56- PE in the monocyte gate.

D. a). d). c). f). b).e). g). Figure S2. NAT2 expression in lymphocytes and monocytes from a tuberculosis patient. PBMC from a tuberculosis patient were double immunostaining for surface markers (CD3, CD19 or CD56) and for intracellular NAT2. D) CD3+NAT2+ cells. a) Dot plots of FSC and SSC. b) Dot plots of anti-CD3-PE and anti-NAT2-FITC in the lymphocyte gate (P1). c) Histogram of anti- NAT2-FITC in the lymphocyte gate. d) Histogram of anti-CD3-PE in the lymphocyte gate. e) Dot plots of anti-CD3-PE and anti- NAT2-FITC in the monocyte gate (P5). f) Histogram of anti-NAT2-FITC in the monocytes gate. g) Histogram of anti-CD3-PE in the monocyte gate.

E. a). d). c). f). b).e). g). Figure S2. NAT2 expression in lymphocytes and monocytes from a tuberculosis patient. PBMC from a tuberculosis patient were double immunostaining for surface markers (CD3, CD19 or CD56) and for intracellular NAT2. E) CD19+NAT2+ cells. a) Dot plots of FSC and SSC. b) Dot plots of anti-CD19-PE and anti-NAT2-FITC in the lymphocyte gate (P1). c) Histogram of anti- NAT2-FITC in the lymphocyte gate. d) Histogram of anti-CD19-PE in the lymphocyte gate. e) Dot plots of anti-CD19-PE and anti-NAT2-FITC in the monocyte gate (P5). f) Histogram of anti-NAT2-FITC in the monocytes gate. g) Histogram of anti-CD19- PE in the monocyte gate.

F. a). d). c). f). b).e). g). Figure S2. NAT2 expression in lymphocytes and monocytes from a tuberculosis patient. PBMC from a tuberculosis patient were double immunostaining for surface markers (CD3, CD19 or CD56) and for intracellular NAT2. F) CD56+NAT2+ cells. a) Dot plots of FSC and SSC. b) Dot plots of anti-CD56-PE and anti-NAT2-FITC in the lymphocyte gate (P1). c) Histogram of anti- NAT2-FITC in the lymphocyte gate. d) Histogram of anti-CD56-PE in the lymphocyte gate. e) Dot plots of anti-CD56-PE and anti-NAT2-FITC in the monocyte gate (P5). f) Histogram of anti-NAT2-FITC in the monocytes gate. g) Histogram of anti-CD56- PE in the monocyte gate.

Figure S3. Negative and Positive controls for NAT2 immunostaining protocol. CHO cells were used as a negative control of NAT2 expression (A-G). HeLa cells were used as a positive control of NAT2 expression (H-N). Dot plots of FSC and SSC for CHO (A) and HeLa cells (H). Dot plots of unstained CHO (B) and HeLa cells (I). Histograms of the unstained CHO (C) and HeLa cells (J). Dot plots of the isotype control-FITC in CHO (D) and HeLa cells (K). Histograms of the isotype control-FITC in CHO (E) and HeLa cells (L). Dot plots of anti-NAT2-FITC in CHO (F) and HeLa cells (M). Histograms of anti-NAT2-FITC in CHO (G) and HeLa cells (N). A. G.F. E. D. C. B. H. N. M. L. K. J. I.